UBS Group’s Advanced Health Intelligence Ltd AHI Stock Holding History

UBS Group’s Portfolio AHI Stock Details AHI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-122	Closed	-$305	–	10622
2023 Q3	$305	Sell	122 -614	-83%	-$2.31K	﹤0.01%	8600
2023 Q2	$2.82K	Buy	+736	New	+$1.66K	﹤0.01%	7687
2023 Q1	–	Sell	-2,426	Closed	-$3.98K	–	11609
2022 Q4	$3.98K	Sell	2,426 -1,042	-30%	-$1.81K	﹤0.01%	9413
2022 Q3	$7K	Buy	3,468 +2,415	+229%	+$6.39K	﹤0.01%	8980
2022 Q2	$2K	Buy	1,053 +549	+109%	+$2.03K	﹤0.01%	9775
2022 Q1	$3K	Buy	+504	New	+$4.23K	﹤0.01%	9594

Other funds holding AHI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

UBS Group's AHI Position: Q4 2023 in Review

UBS Group sold out of Advanced Health Intelligence Ltd (AHI) in Q4 2023, closing a stake of 122 shares — an estimated $305 sold.

UBS Group first reported a position in AHI in Q1 2022 and held it in 6 quarters. The position peaked at $7K in Q3 2022. 3 funds tracked by Wall St. Rank hold AHI as of Q4 2023.

UBS Group reported no remaining Advanced Health Intelligence Ltd position as of Q4 2023 after selling out during the quarter.
UBS Group sold 122 Advanced Health Intelligence Ltd shares in Q4 2023, an estimated $305.
UBS Group first reported a position in Advanced Health Intelligence Ltd in Q1 2022 and held it in 6 quarters.
UBS Group's Advanced Health Intelligence Ltd position peaked at $7K in Q3 2022.
3 funds tracked by Wall St. Rank held Advanced Health Intelligence Ltd as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.